KR20200132893A - 합성 dna 벡터 및 사용 방법 - Google Patents

합성 dna 벡터 및 사용 방법 Download PDF

Info

Publication number
KR20200132893A
KR20200132893A KR1020207028218A KR20207028218A KR20200132893A KR 20200132893 A KR20200132893 A KR 20200132893A KR 1020207028218 A KR1020207028218 A KR 1020207028218A KR 20207028218 A KR20207028218 A KR 20207028218A KR 20200132893 A KR20200132893 A KR 20200132893A
Authority
KR
South Korea
Prior art keywords
dna vector
dna
vector
isolated
heterologous gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207028218A
Other languages
English (en)
Korean (ko)
Inventor
브루스 씨. 슈넵
필립 알. 존슨
Original Assignee
인터갈락틱 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터갈락틱 테라퓨틱스, 인크. filed Critical 인터갈락틱 테라퓨틱스, 인크.
Publication of KR20200132893A publication Critical patent/KR20200132893A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207028218A 2018-03-15 2019-03-15 합성 dna 벡터 및 사용 방법 Ceased KR20200132893A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643336P 2018-03-15 2018-03-15
US62/643,336 2018-03-15
US201862749369P 2018-10-23 2018-10-23
US62/749,369 2018-10-23
PCT/US2019/022511 WO2019178500A1 (en) 2018-03-15 2019-03-15 Synthetic dna vectors and methods of use

Publications (1)

Publication Number Publication Date
KR20200132893A true KR20200132893A (ko) 2020-11-25

Family

ID=67908049

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207028218A Ceased KR20200132893A (ko) 2018-03-15 2019-03-15 합성 dna 벡터 및 사용 방법

Country Status (10)

Country Link
US (2) US20210002667A1 (enExample)
EP (1) EP3765023A4 (enExample)
JP (3) JP2021516953A (enExample)
KR (1) KR20200132893A (enExample)
CN (2) CN117757842A (enExample)
AU (1) AU2019233901A1 (enExample)
CA (1) CA3092088A1 (enExample)
IL (1) IL276923A (enExample)
MX (1) MX2020009579A (enExample)
WO (1) WO2019178500A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
DK3474760T3 (da) 2016-06-27 2023-03-20 Galvanize Therapeutics Inc Generator og et kateter med en elektrode til at behandle en lungepassage
US20200048716A1 (en) * 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
EP4552592A3 (en) 2017-12-26 2025-06-18 Galvanize Therapeutics, Inc. Optimization of energy delivery for various applications
IL326835A (en) * 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes
CN114007535A (zh) 2019-04-18 2022-02-01 盖乐世公司 用于治疗异常组织的装置、系统和方法
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
CN115348844A (zh) 2020-04-08 2022-11-15 盖能适治疗股份有限公司 脉冲电场波形操作和使用
CN116829691A (zh) 2020-08-04 2023-09-29 盖能适治疗股份有限公司 分子到体内细胞的脉冲电场转移
EP4192572A4 (en) 2020-08-04 2024-08-21 Galvanize Therapeutics, Inc. TRANSFER OF MOLECULES BY PULSED ELECTRIC FIELD TO CELLS IN THE ORGANISM
JP2024509084A (ja) * 2021-02-23 2024-02-29 インターギャラクティック セラピューティクス インコーポレイテッド 核酸ベクター及び使用方法
EP4394043A4 (en) * 2021-08-24 2025-09-03 Cells & Genes Biotech Shanghai Co Ltd CELL MODIFICATION METHOD
AU2022367527A1 (en) * 2021-10-15 2024-05-02 Aldevron, Llc Respiratory delivery of therapeutic agents
KR20250011939A (ko) * 2022-05-13 2025-01-22 아시디엔 테라퓨틱스, 인크. Abca4 트랜스-스플라이싱 분자
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
KR20250034991A (ko) 2022-08-16 2025-03-11 알데브론 엘엘씨 합성 환형 핵산 생산을 위한 무세포 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
CN1264854C (zh) * 1999-05-28 2006-07-19 坎布雷科斯生物科学巴尔的摩公司 Dna纯化方法和纯化的dna
EP1224313A1 (en) * 1999-10-07 2002-07-24 University of Iowa Research Foundation Adeno-associated viruses and uses thereof
EP1317560A4 (en) * 2000-09-08 2005-10-05 Gen Hospital Corp DNA VECTORS WHICH COULD REENGANIZE
US20070196838A1 (en) * 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030082559A1 (en) * 2001-01-19 2003-05-01 David Beach Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences
AU2009231171A1 (en) * 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US8945885B2 (en) * 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
CN102083975A (zh) * 2008-07-03 2011-06-01 利兰·斯坦福青年大学托管委员会 小环dna载体制剂及其制备方法和使用方法
EP2439276A1 (de) * 2010-10-05 2012-04-11 Rentschler Biotechnologie GmbH Verfahren zur semi-synthetischen Herstellung hochreiner "MiniCircle" DNA-Vektoren aus Plasmiden
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US10604771B2 (en) * 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
AU2015264263B2 (en) * 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
EP3250685A1 (en) * 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
AU2016260401B2 (en) * 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
AU2016355343C1 (en) * 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Also Published As

Publication number Publication date
EP3765023A1 (en) 2021-01-20
AU2019233901A1 (en) 2020-09-17
JP2026102885A (ja) 2026-06-23
EP3765023A4 (en) 2022-01-19
JP2021516953A (ja) 2021-07-15
US20210002667A1 (en) 2021-01-07
IL276923A (en) 2020-10-29
MX2020009579A (es) 2020-11-09
WO2019178500A1 (en) 2019-09-19
CN111954528A (zh) 2020-11-17
CN117757842A (zh) 2024-03-26
CA3092088A1 (en) 2019-09-19
JP2024041819A (ja) 2024-03-27
US20240247284A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
JP2024041819A (ja) 合成ｄｎａベクターおよびその使用
JP2025176040A (ja) 合成ｄｎａベクターおよびその使用法
KR102832035B1 (ko) 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
CN111819281B (zh) 用于神经变性疾病的基因疗法
KR20200079497A (ko) 제제
WO2003089011A1 (en) rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
EP3569708A1 (en) Aav vector for disrupting clotting-related factor gene on liver genome
CN113906134B (zh) Tau蛋白病模型
CN107384967A (zh) 一种将外源基因定点插入到家蚕w染色体中的方法
CN110484517A (zh) 一种用于制备弱毒的裂谷热病毒的组合物及制备方法，rvfv减毒疫苗
CN114364440B (zh) Aav介导的rpgr x连锁视网膜变性的基因编辑治疗
CN114606251A (zh) 以外泌体为载体的dna递送系统
CN101020064A (zh) 一种布鲁氏杆菌核酸疫苗
Wang et al. Syngeneic AAV pseudo-particles potentiate gene transduction of AAV vectors
KR20250097937A (ko) 최적화된 pah 유전자 및 발현 카세트 및 그의 사용
AU2019265663B2 (en) AAV-compatible laminin-linker polymerization proteins
CN114796526B (zh) 一种仿生双特异性纳米编辑系统及其用途
KR20220122636A (ko) 제1형 당뇨병을 치료하기 위한 대식세포의 췌장 내 m2 분극화
JP2023507174A (ja) Ｄｍｄ変異の修正のための方法及び組成物
KR20220079857A (ko) Aav-상용성 라미닌-링커 중합 단백질
CN113171471B (zh) 一种用于治疗睾丸间质细胞功能障碍的基因药物及应用
CN114940978B (zh) 表达盖他病毒e2蛋白的重组猪繁殖与呼吸综合征病毒的构建方法
CN101659967B (zh) 用于生产转基因猪的piggyBac转座载体及其构建方法
Hu et al. Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases
CN111296364B (zh) 一种基因改造的小鼠动物模型基因改造方法及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000